CompanyDrug

AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals

CompanyDrug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

CompanyDeals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

CompanyDeals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

CompanyDrug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

NMPA Approves World's First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
CompanyDrug

NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal

CompanyDrug

Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers

CompanyDeals

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6
CompanyDrug

Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6

Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms
CompanyDrug

Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms

Others

China’s NMPA Unveils Ambitious “AI + Drug Regulation” Roadmap Through 2035